Navigation Links
Stem Cell Therapy to Skyrocket by 2017
Date:9/13/2007

Although still in its infancy, stem cell therapy market to grow rapidly

over next decade

WALTHAM, Mass., Sept. 13 /PRNewswire/ -- Millennium Research Group (MRG) has conducted a detailed analysis of the stem cell therapy market in its US Markets for Stem Cell Therapies 2007 report. The analysis reveals that although the market for stem cell therapies is in its infancy, it will grow rapidly as products are approved in the US. Today, only two products are on the market, but by 2017, almost 90 are expected to be available.

Stem cells have regenerative capabilities, and promise lasting treatments for chronic disorders and potential cures for currently 'incurable' diseases. In 2007, the US stem cell therapies market earned over $25 million in revenues, with only two orthopedic products available in the US-Osiris Therapeutics' Osteocel, and Blackstone Medical's Trinity. Aside from these two products, the development of the US market for stem cell therapies is largely dependent on the success of clinical trials, regulatory approval, and public acceptance. The first products in the cardiovascular, diabetes, neurological, and tissue and organ stem cell therapy markets are expected to enter the market between 2009 and 2013. The entry of these products will open up a new realm of treatable disorders, offering hope to patients and vast market potential.

"This market has almost everything going its way", says Chris Schutz, senior analyst at MRG. "The big question mark however is the political and public support. The prevalence of potentially treatable disorders, unmet medical needs, rising health care costs, growth in the aging population, and the success of the first stem cell therapy products are all factors that will drive this market upward through 2017."

The US Markets for Stem Cell Therapies 2007 report includes coverage of companies offering or developing products for the stem cell therapy market, including Aastrom Biosciences, Advanced Cell Technologies, Arteriocyte, Blackstone Medical, Cytori Therapeutics, Geron, Harvest Technologies, International Stem Cell Corporation, and Osiris Therapeutics.

About Stem Cells

Stem cells are primal cells that are derived from highly proliferative tissues. These cells are precursors to every organ, tissue, and cell in the human body. Because of their universality and ability to repair or replace damaged tissue, stem cells have the potential to cure injuries and diseases such as orthopedic degenerative disease, cardiovascular disease, diabetes, neurological disease, cancer, retinal disease, and other chronic and autoimmune disorders.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Millennium Research Group
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
3. TomoTherapy opens technical training center
4. TomoTherapy raises $223 million in IPO
5. TomoTherapy revises IPO money target
6. Stem cell therapy shows visionary promise
7. Hospital named for Madame Curie installs TomoTherapy system
8. TomoTherapy files registration statement for IPO
9. TomoTherapy to sell medical devices in India
10. TomoTherapy sees sustained market advantage
11. Mirus granted European patent for gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose ... lengthy trial and error process by finding the right antidepressant faster. CNSDose ... the doctor-patient relationship through a personalized approach to treatment. , A ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs ... the Prince Of Wales Private Hospital. The procedure was performed on a 46-year-old ... failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is ...
(Date:5/18/2017)... ... 17, 2017 , ... NDA Partners Chairman Carl Peck, MD , announced ... Laboratories and President of Pharmaceutical Development Business Unit of Cardinal Health, has joined the ... Health, he was former Chief Operating Officer at Anaborex, Senior VP and General Manager ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM ... firm for the life sciences and healthcare industries, is honored that Jay ... Medical Devices conference in Brussels, Belgium. , Crowley played a crucial role in ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):